Safety Issue Scampers AstraZeneca's Obesity Trial
Though, the obesity drug clinical trial has been stopped in its early stage but AstraZeneca and Palatin are still in collaboration and focusing on further clinical products and aspects of research.
San Francisco (I-Newswire) November 8, 2012 - AstraZeneca, one of the top worldwide pharmaceutical companies has to shelve off its early-stage clinical study allied to the obesity medication within a few weeks of the research initiation.
This cessation of the clinical study was forced to be called off following an apparent allergic complication in one of the enrolled 72 patients.
This is one of the main research studies that Palatin Technologies has approved in their 5 year old partnership with the AstraZeneca drug manufacturing company. Currently, the company plans to shift its focus on other clinical tie-ups and start working with them. AstraZeneca has been forced to write off an early-stage obesity drug.
This is the latest setback to the pharmaceutical company in a long term clinical drawbacks but the company has taken an initiate to kick start its pipeline projects with new zeal and enthusiasm.
Dr Carl Spana, CEO of Palatin said that the drug AZD2820 is one of the major R&D collaboration of the company with AstraZeneca; but they do have various other coalition compounds that are in their initial stage of clinical testing. AstraZeneca and partner Palatin Technologies have halted a Phase I trial of an investigational obesity drug after a participant fell ill.
He also added that AstraZeneca will remain committed to them about the clinical advancements in the obesity treatment approach of the collaboration compounds.
The drug code named as AZD2820, functions as a partial agonist of melanocortin-4 receptor peptide to carry out the anti-obesity
The deal was signed in the year 2007 but the unexpected side effect gave a big blow to the clinical targets of the company although, the patients experiencing the allergic manifestation recovered from the condition completely.
For more please visit our site : http://www.carepharmacyrx.com/
Mission & Valencia Sts,
San Francisco, California
Jack is a Medical Student and a freelancer who is specialized in writing. He is associate with many Pharmacies for whom he writes articles based on generic drugs and general health related issues.
carepharmacyrx.com is an online generic medical store. its thing lies in its excellence service and More..consumer centric approach, which makes our online store different and very unique from other online medical store in available in the internet market. making each consumer fulfilled is what we always struggle for. this site is very easy to use and we offer medications at now one click to people all across the earth at cheaper prices. our site provides branded as well as generic medications at reasonable costs.
Mission & Valencia Sts, CA
Phone : 011-6654789986
Published in:Health & Fitness
Published On:November 8, 2012
Print Release:Print Release
If you have questions regarding information in this press release contact the company listed above. I-Newswire.com is a press release service and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter, make sure to check the official company website for accurate release dates as our site displays the I-Newswire.com press release distribution date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for or omissions in that information or for actions taken in reliance on that information.
Caring for the Male Organ with Shea Butter - Tips for a Healthy, Responsive Manhood
Studies Prove That E Cigar Reduce Consumption of Tobacco Among Teenagers and Adults
Get Rid of Man Boobs and Love Handles Fast
Coconut Oil for Acne
Axio Labs Guarantees You Affordable Research Chemicals